Prostate cancer Archives

Dr. Bo Dai: Research Progress in ASCO-GU 2023 prostate cancer

By Mourabit Halima 2024.01.18

The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium for 2023 (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. Numerous innovative treatment studies have emerged in the fields of metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and early/localized prostate cancer. These studies encompass a wide range of therapies, including androgen deprivation therapy (ADT), novel hormonal therapy (NHT), PARP inhibitors (PARPi), immunotherapy, nuclear medicine therapy, and localized treatments.

Prostate Cancer Radiation Therapy Research: SBRT vs Surgery; Conventional Radiation vs Large Fraction Radiation

By Mourabit Halima 2024.01.17

The 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of prostate cancer radiation therapy, two phase 3 clinical studies were selected for oral presentation: The PACE-A study explores stereotactic body radiation therapy (SBRT) compared to surgery for localized prostate cancer; The CHHiP study further reports survival and comorbidity outcomes with a 12-year follow-up.

Dr. Yao Zhu talks to Dr. Nguyen: Advances in Radiotherapy and Surgical Treatment of Prostate Cancer at ASCO-GU 2023

By Mourabit Halima 2024.01.17

The 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU 2023) has concluded. During this conference, several studies related to early-stage/ localized prostate cancer radiotherapy or surgical treatment were presented as oral reports. Among them, the FORMULA-509 study presented by Dr. Paul L. Nguyen of the Dana-Farber Cancer Institute at Harvard Medical School showed that for high-risk patients with biochemical recurrence after radical surgery, combining 6 months of ADT (Androgen Deprivation Therapy) with novel hormonal therapy on top of salvage radiotherapy can improve patient survival. "Oncology Frontier" invited Dr. Zhu Yao from Fudan University Shanghai Cancer Center to have a discussion with Dr. Nguyen, delving into the interpretation of the FORMULA-509 study and other prostate cancer surgery and radiotherapy-related research presented at the conference.

Two Studies of Dr. Yong Xu’s Team at the 2023 EAU Congress, Provided New Insights into Prostate Cancer Biopsies

By Mourabit Halima 2024.01.15

The 38th Annual Congress of the European Association of Urology (EAU23) took place in Milan, Italy, from March 10 to 13, 2023. EAU Congress is one of the most highly anticipated urology conferences in Europe and worldwide, attracting over 15,000 urology experts from around the globe each year. At this year's EAU Congress, Dr. Yong Xu's team from the Second Hospital of Tianjin Medical University had two related studies on prostate cancer selected for presentation, exploring radical excision surgery without biopsies for highly suspicious prostate cancer patients and comparing regional saturation biopsies to targeted biopsies for initial evaluation of suspected prostate cancer patients. These research findings offer new perspectives on prostate cancer biopsies and non-invasive diagnostics.